BioCryst to Report Third Quarter 2021 Financial Results on November 3

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced plans to report its third quarter 2021 financial results on November 3, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the call via phone or a live webcast on the company’s website. BioCryst focuses on discovering novel, oral medications for rare diseases, with products like ORLADEYO approved in multiple regions and ongoing development programs for other treatments, including BCX9930 and BCX9250.

Positive

• Upcoming financial results announcement on November 3, 2021 can provide fresh insights into the company's performance.
• Presence of approved drugs like ORLADEYO, which can support revenue generation.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 2592545. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 2592545.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals report its Q3 2021 financial results?

BioCryst Pharmaceuticals will report its third quarter 2021 financial results on November 3, 2021.

What time is the BioCryst Pharmaceuticals conference call on November 3, 2021?

The conference call will take place at 8:30 a.m. ET on November 3, 2021.

How can I access the BioCryst Pharmaceuticals Q3 2021 earnings call?

The earnings call can be accessed via phone or through a live webcast on BioCryst's website.

What is the focus of BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals focuses on discovering oral medicines to treat rare diseases with unmet medical needs.